JP2020504763A - メチルフェニデートを用いてadhdを処置するための小児の有効な投薬 - Google Patents

メチルフェニデートを用いてadhdを処置するための小児の有効な投薬 Download PDF

Info

Publication number
JP2020504763A
JP2020504763A JP2019544799A JP2019544799A JP2020504763A JP 2020504763 A JP2020504763 A JP 2020504763A JP 2019544799 A JP2019544799 A JP 2019544799A JP 2019544799 A JP2019544799 A JP 2019544799A JP 2020504763 A JP2020504763 A JP 2020504763A
Authority
JP
Japan
Prior art keywords
methylphenidate
drug
individual patient
weight
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019544799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504763A5 (enExample
Inventor
マーク テングラー,
マーク テングラー,
ネイサン トイシャー,
ネイサン トイシャー,
Original Assignee
ネオス・セラピューティクス・エルピー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオス・セラピューティクス・エルピー filed Critical ネオス・セラピューティクス・エルピー
Publication of JP2020504763A publication Critical patent/JP2020504763A/ja
Publication of JP2020504763A5 publication Critical patent/JP2020504763A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00ICT specially adapted for the handling or processing of medical references
    • G16H70/40ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
JP2019544799A 2016-11-01 2017-10-31 メチルフェニデートを用いてadhdを処置するための小児の有効な投薬 Pending JP2020504763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415884P 2016-11-01 2016-11-01
US62/415,884 2016-11-01
PCT/US2017/059256 WO2018085256A1 (en) 2016-11-01 2017-10-31 Effective dosing of a child for the treatment of adhd with methylphenidate

Publications (2)

Publication Number Publication Date
JP2020504763A true JP2020504763A (ja) 2020-02-13
JP2020504763A5 JP2020504763A5 (enExample) 2020-12-10

Family

ID=62076554

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019544799A Pending JP2020504763A (ja) 2016-11-01 2017-10-31 メチルフェニデートを用いてadhdを処置するための小児の有効な投薬

Country Status (6)

Country Link
US (1) US11166947B2 (enExample)
EP (1) EP3585439A4 (enExample)
JP (1) JP2020504763A (enExample)
KR (2) KR20240033130A (enExample)
AU (1) AU2017353921B2 (enExample)
WO (1) WO2018085256A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023518871A (ja) * 2020-03-23 2023-05-08 ジェネンテック, インコーポレイテッド 深層学習を使用した薬物動態パラメータの推定

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003622A1 (en) * 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
US20140287041A1 (en) * 2012-08-15 2014-09-25 Tris Pharma Inc Methylphenidate Extended Release Chewable Tablet
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003622A1 (en) * 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
US20140287041A1 (en) * 2012-08-15 2014-09-25 Tris Pharma Inc Methylphenidate Extended Release Chewable Tablet
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
日薬理誌, vol. 128, JPN6021028523, 2006, pages 8 - 12, ISSN: 0004555393 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023518871A (ja) * 2020-03-23 2023-05-08 ジェネンテック, インコーポレイテッド 深層学習を使用した薬物動態パラメータの推定
JP7577756B2 (ja) 2020-03-23 2024-11-05 ジェネンテック, インコーポレイテッド 深層学習を使用した薬物動態パラメータの推定
US12400734B2 (en) 2020-03-23 2025-08-26 Genentech, Inc. Estimating pharmacokinetic parameters using deep learning

Also Published As

Publication number Publication date
KR20190107655A (ko) 2019-09-20
AU2017353921A1 (en) 2019-06-13
US20190314356A1 (en) 2019-10-17
KR20240033130A (ko) 2024-03-12
WO2018085256A1 (en) 2018-05-11
US11166947B2 (en) 2021-11-09
AU2017353921B2 (en) 2023-11-09
EP3585439A4 (en) 2020-07-22
EP3585439A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
Derendorf et al. Rowland and Tozer's clinical pharmacokinetics and pharmacodynamics: concepts and applications
Swanson et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study)
Brody et al. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors
ES3025836T3 (en) Use of pridopidine for treating functional decline
Bontempo et al. D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis
Gotta et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
AU2017315781A1 (en) Use of pridopidine for treating dystonias
JP2012517449A (ja) アミノピリジンによる長期治療のための組成物及び方法
Childress et al. Single-dose pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate formulation, in healthy adults and in adolescents and children with attention-deficit/hyperactivity disorder
Sullivan et al. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone
Hsu et al. The influence of light administration on interpersonal behavior and affect in people with mild to moderate seasonality
Fuchs et al. Efficacy of isolated home blood pressure monitoring for blood pressure control: randomized controlled trial with ambulatory blood pressure monitoring–MONITOR study
JP2020504763A (ja) メチルフェニデートを用いてadhdを処置するための小児の有効な投薬
Shram et al. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria
Rajendram et al. Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial
Abdelgawad et al. Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis
Wang et al. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (A lliance)
Lim et al. Pharmacokinetic‐pharmacodynamic modeling of intravenous and oral topiramate and its effect on the symbol‐digit modalities test in adult healthy volunteers
Maclean et al. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
Liu et al. Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET‐Altered Metastatic Thyroid Cancer or Solid Tumors
Johnson et al. Methods for Assessing the Adherence to Medical Devices
JP7542539B2 (ja) 注意欠陥多動性障害を処置するためのメチルフェニデート組成物
Upton U-RHYTHM microdialysis: towards ambulatory metabolodynamics
Gao et al. A randomized, open‐label, 3‐way crossover study to demonstrate bioequivalence of sildenafil powder for oral suspension with tablets used commercially and in clinical studies for the treatment of pulmonary arterial hypertension
TW202438060A (zh) 用於治療夏柯-馬利-杜斯氏症的組成物及方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220222